Ignite Creation Date:
2024-05-06 @ 8:24 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06375993
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-05
First Post:
2024-04-17
Brief Title:
A Phase 1 Study of ADI-001 in Lupus Nephritis
Sponsor:
Adicet Therapeutics
Organization:
Adicet Therapeutics
Study Overview
Official Title:
A Phase 1 Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta γδ T Cells in Adults With Lupus Nephritis
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
ADI-202300103 is a phase 1 multicenter open label dose finding and dose expansion safetyefficacy study in patients with lupus nephritis The study will consist of different periods including screening lymphodepletion treatment and follow-up
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None